#16
|
|||
|
|||
Âûÿâëåí ÂÀ
Ê ñîæàëåíèþ ó íàøåé ïàöèåíòêè ìû îáíàðóæèëè ÂÀ, òàê ÷òî ÀÊ òåðàïèÿ âåðîÿòíî çàòÿíåòñÿ íà áîëåå ïðîäîæèòåëüíûé ñðîê íåæåëè 3 ìåñÿöà.
|
#17
|
||||
|
||||
Êîëÿ, âî ñêîëüêî ðàç óäëèíåíû êîàã. òåñòû è êàêèå? Íà ñêîëüêî óäëèíåíû ïîñëå äîáàâëåíèÿ êîíòð. ïëàçìû è èíêóáàöèè â òå÷åíèå 1 ÷ 37Ñ, êîððåêòèðîâàëè ðàçìîðîæåííûìè òðîìáîöèòàìè èëè åñòü ó âàñ ñïåö. ôîñôîëèïèäû äëÿ íåéòðàëèçàöèè?
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#18
|
|||
|
|||
ÂÀ
Äîðîãîì ìîé Âàäèì,
ÂÀ ìû âûÿâëÿëè ñòàíäàðòíûì òåñòîì DADE Ber. ËÀ1 = 64 ñåê, ËÀ2 = 32 ñåê, ËÀ1/ËÀ2 = 2, Ìèêñò òåñòîâ ìû íå äåëàëè ïîñêîëüêó íå âèäåëè ñìûñëà (åñòü óäëèíåíèå ËÀ1 è åãî êîððåêöèÿ â èçáûòêå ÔË - íîðìàëüíûé ËÀ2). Ðàäá ÷òî òû íàêîíåö ïîäêëþ÷èëñÿ ê íàøåìó ìèëîìó îáñóæäåíèþ, ìîæåò ÷òî ïîäñêàæåøü ïî ïîâîäó ÍÀÊ äëÿ òåòè? Ñ ïàðèâåòîì Ä-ð Îãàíåñÿí Í.À. |
#19
|
||||
|
||||
Íè÷åãî íîâîãî òåáå íå îòêðîþ:
2.1.4. For patients with a first episode of DVT who have documented antiphospholipid antibodies or who have two or more thrombophilic conditions (eg, combined factor V Leiden and prothrombin 20210 gene mutations), we recommend treatment for 12 months (Grade 1C+). We suggest indefinite anticoagulant therapy in these patients (Grade 2C). (Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy) Åäèíñòâåííî, ìîæåòå ïîïðîáîâàòü - ÷åðåç ÷åðåç ãîä îòìåíèòü âàðôàðèí è ÷åðåç ìåñÿö ïîñëå îòìåíû ïîñìîòðåòü ÄÄ - áóäåò ïîâûøåí, òîãäà óæ "indefinite anticoagulant therapy" Ýòî èäåò èç N Engl J Med. 2006 Oct 26;355(17):1780-9. D-dimer testing to determine the duration of anticoagulation therapy. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AW, Tripodi A; PROLONG Investigators. Åñëè áóäåò â íîðìå, òî òåñòèðóåòå Ä-äèìåð åæåìåñÿ÷íî è åñëè ïîâûñèòñÿ, òîãäà âîçîáíîâëÿåòå (äàííàÿ ìåòîäèêà ñåé÷àñ àïðîáèðóåòñÿ â PROLONG II, íî ïðèìåíÿåòñÿ íà ïðàêòèêå îòäåëüíûìè äîêòîðàìè).
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#20
|
|||
|
|||
Âàäèì Âàëåðè÷
Âñå ýòî ïîíÿòíî, íî åñëè íà âàðôàðèíå ìû ýôôåêòà íå ïîëó÷èì (óæå äîçà 12,5 ìã,à ÌÍÎ òîëüêî 1,41). ÍÌà ìû âîçîáíîâèëè, íî âåñòè åå íà íåì ãîä è áîëåå áóäåò íàêëàäíî. Êîíå÷íî ìû ìîæåì âåñòè åå òîëüêî íà ÍÌà îðèåíòèðóÿñü íà Ä-äèìåðû ïåðèîäè÷åñêè îòìåíÿòü ÍÌÃ, íî òàêàÿ òàêèêà ÷ðåâàòà, ïîñêîëüêó íå îòðàáîòàíà. Ñ ïðèâåòîì Ä-ð Í. Îãàíåñÿí |
#21
|
||||
|
||||
Ñåé÷àñ ãëàâíîå äîéòè äî öåëåâûõ ÌÍÎ: íèçêèå çíà÷åíèÿ íåñìîòðÿ íà âûñîêóþ äîçó âàðôàðèíà ãîâîðÿò èëè îá îòíîñèò. ðåçèñòåíòíîñòè (áûòü ìîæåò, ñâÿç. ñ îñîáåííîñòÿìè ìåòàáîëèçìà ó äàííîãî èíäèâèäà) èëè ñêîðåå î òîì, ÷òî â îðãàíèçì ïîñòóïàåò äîñòàòî÷íî áîëüøîå êîëè÷åñòâî âèò. Ê (èëè ñ ïèùåé èëè ÷åðåç êèøå÷íóþ "ôëîðó è ôàóíó"), ïîýòîìó ïîêà ðàâíîâåñèÿ íå ïîëó÷èòå (õîòü íà 20 ìã â ñóòêè), òî äîêàëûâàéòå ÍÌÃ. Ïåðèîäè÷åñêîå íàçíà÷åíèå ÍÌà ëó÷øå íå ïðîáîâàòü, òîãäà óæ áîëüøå ðàöèîíàëüíîñòè â òàêòèêå à-ëÿ ïîääåðæàíèå ÌÍÎ áîëåå 1,5 ïëþñ àñïèðèí.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#22
|
|||
|
|||
Öèòàòà:
... âåäü âàðôàðèí óâåëè÷èâàåò íå òîëüêî ÏÈ, íî- è À×ÒÂ. Îáû÷íî, êîíå÷íî, â ìåíüøåé (èëè ðàâíîé) ñòåïåíè, íî- âñåãäà ëè? À îò ðåøåíèÿ- åñòü ÂÀ, èëè-íåò- çàâèñèò âåñüìà ìíîãî, êîå-êòî ðåêîìåíäóåò ïîæèçíåííóþ òåðàïèþ, íåò? ...ïðîñòî â âèäå ðàçìûøëåíèÿ- à âîò äîñòàòî÷íî ëè îäíîãî ÂÀ â äàííîì êîíêðåòíîì ñëó÷àå? À íå âçÿòü ëè àíòèòåëà ê êàðäèîëèïèíó? (...è åñëè ïîëîæèòåëüíûå- íå ïåðåïðîâåðèòü ëè åøå è íà ñèôèëèñ....) |
|
#23
|
||||
|
||||
Óâàæàåìûé Àíòîí,
Ýòîò òåñò ìàëî÷óâñòâèòåëåí ê âàðôàðèíó (òåì áîëåå íà òàêèõ ÌÍÎ): Thromb Haemost. 1985 Oct 30;54(3):709-12. The dilute phospholipid APTT: a sensitive assay for verification of lupus anticoagulants. Alving BM, Baldwin PE, Richards RL, Jackson BJ. A simple sensitive method for verification of lupus anticoagulants utilizing dilution of phospholipid in the activated partial thromboplastin time (APTT) system is described. Patient plasma, mixed with an equal volume of normal plasma, is activated with micronized silica. To this mixture are added different dilutions of Thrombofax and then calcium chloride. Clotting times are plotted linearly against the logarithm of the phospholipid dilutions and slopes are calculated by regression analysis. In this assay the mean negative slope of 19 plasmas that contained anti-phospholipid activity was five times greater than those of normal plasma or those obtained from patients having single or multiple coagulation factor deficiencies such as those induced by warfarin. The assay can be modified to test heparinized plasmas. Thus, it is a sensitive means by which to verify the presence of lupus anticoagulants in patients who have congenital or acquired factor deficiencies or who are receiving anticoagulant therapy.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#24
|
|||
|
|||
ñïàñèáî çà ññûëêó.
Âàäèì, ýòîò òåñò íàñòîëüêî õîðîø è ñòàíäàðòèçîâàí- ÷òî "ìèêñèí' " ïðè ÂÀ áîëüøå íå íóæíû? ...È åøå- êàêîâî "ïðàêòè÷åñêàÿ íèøà" ÂÀ è àíòèòåë ê êàðäèîëèïèíó, èõ "óäåëüíûé âåñ" â äèàãíîñòèêå? Åñòü ëè ðåêîììåíäàöèè/íàáëþäåíèÿ ó îòäåëüíûõ ãðóïï áîëüíûõ- ó îäíèõ, ìîë, ñ òðîìáîçàìè áîëåå êîððåëèðóåò ÂÀ, à ó äðóãèõ- àíòèòåëà ê ÊË? |
#25
|
||||
|
||||
Âñå äåéñòâèòåëüíî òàê - ìèêñèíã òåîðåòè÷åñêè íóæåí, íî èñïîëüçîâàíèå 2 òèïîâ APTT ðåàãåíòîâ, ïîõîæå, êàê ðàç è âûïîëíÿåò ýòó ôóíêöèþ: âûÿâëåíèå ÂÀ ïðîèçâîäèòñÿ ðåàãåíòîì ñ íèçêèì ñîäåðæàíèåì ôîñôîëèïèäîâ, à ïîäòâåðæäåíèå èäåò ðåàãåíòîì ñ èçáûòêîì ôîñôîëèïèäîâ (àíàëîãè÷íî ïðîöåäóðå íåéòðàëèçàöèè). Ïîëó÷àåòñÿ, ÷òî ôàçà âûÿâëåíèÿ àíòèòåëüíîãî óãíåòåíèÿ ïðîöåññà êîàãóëÿöèè (ìèêñèíã ñ íîðìàëüíîé ïëàçìîé è óäëèíåíèå òåñòà ïîñëå 37Ñ-èíêóáàöèè) îïóñêàåòñÿ, òàê êàê ñðàçó èäåò ïîäòâåðæäåíèå ôîñôîëèïèä-çàâèñèìîé ïðèðîäû óâåëè÷åíèÿ APTT, ÷òî õàðàêòåðíî èñêëþ÷èòåëüíî äëÿ ÂÀ.
Òåñò âïåðâûå îïèñàí çäåñü: Blood Coagul Fibrinolysis. 1997 Apr;8(3):155-60. A rapid screen for lupus anticoagulant with good discrimination from oral anticoagulants, congenital factor deficiency and heparin, is provided by comparing a sensitive and an insensitive APTT reagent. Brancaccio V, Ames PR, Glynn J, Iannaccone L, Mackie IJ. Haematology Department, Cardarelli Hospital, Naples, Italy. Lupus anticoagulants (LA) are associated with an increased risk of thrombosis and laboratory detection is of major importance. Various tests are available for LA screening and confirmation, but they differ in sensitivity and specificity, frequently lacking the ability to discriminate between the presence of LA, heparin and oral anticoagulants. We noticed that a patient with LA who had a prolonged activated partial thromboplastin time (APTT) by our routine method, gave a normal result with a different APTT reagent. This latter reagent, which contained soy bean phosphatides (SBP), was compared with a reagent containing rabbit brain phospholipids complexed with kaolin (RBK), for APTT measurement in a variety of patients. There was no significant difference in APTT ratio between the two reagents in plasma samples from healthy normal subjects. In LA samples, SBP gave consistently lower APTT ratios than RBK (mean +/- SEM, 1.04 +/- 0.05 and 2.08 +/- 0.19 for SBP and RBK respectively; P < 0.001). In LA patients receiving oral anticoagulants for antithrombotic prophylaxis or treatment, the APTT ratio was again significantly shorter with SBP (1.60 +/- 0.17 and 3.40 +/- 0.67; P < 0.05). In LA negative patients receiving oral anticoagulants, the relationship was reversed, and a higher APTT ratio was obtained with SBP than RBK (1.61 +/- 0.13 and 1.31 +/- 0.12; P < 0.001). In addition, there were no significant differences in APTT ratios for the two reagents when samples from patients receiving heparin therapy, or patients with acquired factor VIII deficiency or inherited deficiency of factor VIII or IX were studied. The use of the SBP reagent alongside a LA sensitive APTT reagent allows a rapid screening for LA, as well as a confirmation of the phospholipid dependency of the inhibitor. Íèæå ôðàãìåíòû íåäàâíåãî ìåæäóíàðîäíîãî êîíñåíñóñà, ãäå è îòâåòû íà Âàøè âîïðîñû (âêðàòöå - ÂÀ è àíòèòåëà ê áåòà2ãëèêîïðîòåèíó ëó÷øå êîððåëèðóþò ñ êëèíè÷åñêèìè ïðîÿâëåíèÿìè/òðîìáîçàìè íåæåëè àíòèêàðäèîëèïèíîâûå ÀÒ, è ïîõîæå èõ ñêîðî çàìåíÿò íà îïðåäåëåíèå àíòèòåë ê áåòà2ãëèêîïðîòåèíó): Lupus anticoagulant better correlates with thrombosis (Evidence Level I) [75], pregnancy morbidity (Evidence Level II) [76], and thrombosis in SLE patients (Evidence Level I) [77] than does aCL. No definite recommendation can be given on the assays of choice for LA testing. Both activated partial thromboplastin time (APTT)-based assays and dilute Russell's viper venom time (dRVVT) are suitable for LA (Evidence Level II) [79,80], provided that the APTT used for LA testing is LA sensitive. One positive test suffices for LA positivity; as no single test is 100% sensitive for LA, it is advised to use two or more tests with different assay principles before the presence of LA is excluded. If the patient is on oral anticoagulants, measurement of LA is better postponed (Evidence Level III) [84], or patient samples be diluted 1 : 2 with normal plasma before the test is performed, provided that international normalized ratio (INR) is <3.5. When INR is >3.5, the LA testing is unworkable (Evidence Level IV). Several phospholipids (rabbit brain extract, hexagonal phase phospholipids, defined phospholipid vesicles, washed-activated platelets, frozen-thawed platelets and lyophilized platelet extracts) have been used successfully in LA confirmation assays; no evidence exists for superiority of any particular one. The ISTH-SSC recommended in 2002 that the aCL test should be replaced by anti-β2GPI and the LA tests [97]. However, the best available evidence indicates that anti-β2GPI cannot yet be considered a substitute for aCL (Evidence Level II) [21,22,98]; this committee recommends that aCL continue to be a laboratory criterion for APS. By majority2, the committee agreed that IgG and IgM anti-β2GPI should be included as part of the modified Sapporo criteria. Anti-β2GPI antibodies are an independent risk factor for thrombosis (Evidence Level II) [107,108] and pregnancy complications (Evidence Level I) [109,110], though some studies deny these associations mainly because of methodological differences and lack of standardization [107,108]. Inter-laboratory variation of anti-β2GPI is better than that found with the aCL assay for both home-made [111] and commercial kits [112] (Evidence Level II). The anti-β2GPI assay shows higher specificity than aCL for APS diagnosis (Evidence Level II) [21,22,113–115]. In 3–10% of APS patients, anti-β2GPI may be the only test positive (Evidence Level I) [23,98,116]. The association of anti-β2GPI with pre-eclampsia and/or eclampsia in unselected pregnant women who tested negative for aCL (Evidence Level I) [109] implies that the inclusion of anti-β2GPI may also help clarify this pregnancy morbidity. Èç International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) Journal of Thrombosis and Haemostasis Volume 4 Issue 2 Page 295 - February 2006
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#26
|
|||
|
|||
Öèòàòà:
![]() ñïàñèáî åøå ðàç |
#27
|
||||
|
||||
Àíòîí, åñëè ïî-ñåðüåçíîìó, òî òå çíà÷åíèÿ ÌÍÎ (1,3...1,4), íà êîòîðûõ äèàãíîñòèðîâàëè ÂÀ, ìàëî ÷åì îòëè÷àþòñÿ îò âåðõíåé ãðàíèöû íîðìû 1,2, ïîýòîìó òàêîé ãèïîêîàãóëÿöèåé ìîæíî ïðåíåáðå÷ü.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |